TWP
VRTX icon

Triad Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Triad Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
+441
New +$195K 0.01% 543
2024
Q3 		– Sell
-4
Closed -$1.88K – 910
2024
Q2 		$1.88K Buy
+4
New +$1.74K ﹤0.01% 771

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Triad Wealth Partners's VRTX Position: Q2 2026 in Review

Triad Wealth Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 441 shares worth $208K. The stake represents 0.01% of the portfolio and ranks #543 among its holdings. This is a return to the name: Triad Wealth Partners previously reported a position in VRTX as recently as Q2 2024.

Triad Wealth Partners first reported a position in VRTX in Q2 2024 and has held it in 2 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Triad Wealth Partners held 441 shares of Vertex Pharmaceuticals worth $208K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Triad Wealth Partners position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Triad Wealth Partners's portfolio in Q2 2026, its #543 holding.
  • Triad Wealth Partners first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Triad Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.